Financial Disclosures: Dr Chabner has consulted
for or served on the advisory boards of Cephalon, Gloucester Pharmaceuticals,
Baxter Oncology, Kosan Biosciences, Oncotech, Pharmamar, Cell Genesys, Eli
Lilly, and Johnson & Johnson and has equity, ownership, or stock options
in Pharmamar, Kosan Biosciences, Oncotech, Cell Genesys, and Vion Pharmaceuticals.
Dr Finkelstein has received grants and consulting fees from Merck, Millenium
Pharmaceuticals, Amgen, and Thompson Medstat.
Author Contributions: Dr Roberts had full access
to all of the data in the study and takes responsibility for the integrity
of the data and the accuracy of the data analyses.
Study concept and design: Roberts, Stallings,
Chabner, Finkelstein, Clark.
Acquisition of data: Roberts, Goulart, Squitieri,
Analysis and interpretation of data: Roberts,
Goulart, Halpern, Chabner, Gazelle, Clark.
Drafting of the manuscript: Roberts.
Critical revision of the manuscript for important
intellectual content: Goulart, Stallings, Halpern, Chabner, Gazelle,
Statistical analysis: Roberts, Halpern.
Obtained funding: Roberts, Stallings, Gazelle,
Administrative, technical, or material support:
Goulart, Squitieri, Stallings.
Study supervision: Roberts, Chabner, Finkelstein,
Funding/Support: This study was supported in
part by a grant from the Alfred P. Sloan Foundation. Dr Roberts’ salary
was supported by a Cancer Outcomes Research and Training grant funded by the
National Cancer Institute (R25T CA 92203). After the study was completed,
Dr Roberts became the recipient of an unrestricted Health Outcomes Research
Starter Grant from the PhRMA Foundation, which is being used to support research
assistance in a separate project.
Role of the Sponsor: The sponsors had no role
in the conception or design of the study; collection, analysis, or interpretation
of the data; or drafting or revision of the manuscript.
Previous Presentation: Parts of this work were
submitted for presentation at the annual meeting of the American Society of
Clinical Oncology; June 5-8, 2004; New Orleans, La.
Acknowledgment: We thank Joseph Paul Eder,
MD, of the Dana Farber Cancer Institute and Thomas Lynch, MD, Jeffrey Supko,
PhD, and Karen Donelan, ScD, of the Massachusetts General Hospital for their
helpful discussions, support, and reviews of the manuscript. We also thank
Ilan Guedj of the MIT Sloan School of Management and David Scharfstein, PhD,
of the Harvard Business School for their insight and assistance. Dr Roberts
is indebted to Maureen Lucey for help in preparing the manuscript.